Richard Edelson

Last updated
Richard Edelson
Alma materYale School of Medicine
EmployerYale School of Medicine
TitleBrady Professor of Dermatology

Richard Edelson is the Anthony Brady Professor of Dermatology at the Yale School of Medicine. He is a past director of the Yale Cancer Center, and an elected fellow of both the American Society for Clinical Investigation and the Association of American Physicians. He is known for his research discoveries in non-Hodgkins lymphoma, particularly his early career introduction of the disease category concept of Cutaneous T Cell Lymphoma (CTCL), and his discovery of extracorporeal photochemotherapy (ECP) as an immunotherapy for cancer, transplant reactions and autoimmunity.

Contents

Early life and education

Richard Edelson grew up in New Jersey, where his father ran a dermatology practice. [1] Edelson graduated from Hamilton College with an undergraduate degree in Chemistry, before earning his MD at the Yale School of Medicine in 1970. Following his graduation, at the height of the Vietnam War, Edelson applied to perform research at the National Institutes of Health (NIH), and, as formally part of the Navy, fulfilled the mandatory military service obligation. These positions combined “highly specialized clinical care with advanced scientific research” according to Yale Medical School. [1] He then was further trained in Internal Medicine at the University of Chicago and Dermatology at Harvard. [2]

Early career

When at the NIH, he was assigned to the National Cancer Institute, from 1972 to 1975, where he held the rank of Lieutenant Commander and simultaneously was an immunology research fellow at the National Cancer Institute and was in charge of lymphoma patients. Here he discovered that lymphoma with prominent skin involvement was commonly a special kind of cancer, which he entitled ‘cutaneous T-cell lymphoma” or CTCL. [1] [3] He next became an assistant professor of dermatology at Columbia College of Physicians and Surgeons. [4] Edelson credits his time at NCI for inspiring him to pursue a career in cancer immunology, while studying early T cell biology. He became a full professor at Columbia in 1980. [1]

While at Columbia, he served as Director of the Immunobiology Group in Columbia University's nationally designated Comprehensive Cancer Center. In 1982 he invented the photopheresis treatment of CTCL. The process drained blood from the patient using an IV, in order to use the photoactivated DNA-crosslinking drug methoxsalen outside of the body in order to kill cancer cells before returning the blood into the patient’s body. Initially, he believed that this would be a stalling tactic for the cancer’s growth, however it cured two of the first five patients of their condition after just three sessions. In the long run, this led to his team’s discovery of the process where the body signals monocytes to become dendritic cells, the master switch of the selective human immune system. In 1988 Edelson’s invention, became the first immunotherapy for any cancer to be approved by the FDA. [1] He also served as Associate Director of Columbia's General Clinical Research Center and Professor and Director of Research in Columbia's Dermatology Department.

In 1986 he was recruited by a national search committee to return to the Yale School of Medicine as Tenured Professor and Chairman of the Yale Department of Dermatology. [2] He held that position for 37 years until 2022, completing one of the longest departmental chairmanships in the history of Yale University. While remaining a full-time Yale faculty member, he elected to relinquish his major administrative responsibilities to focus on his research team's efforts to extend his career-long efforts to produce T cell-based individualized cancer vaccines for the treatment of a broad range of immunogenic malignancies, permissive control of transplanted organs (heart, lung, liver and kidneys), as well as autoimmune disorders (lupus, scleroderma, rheumatoid arthritis, diabetes and blood dyscrasias).

Yale career

While department chair, Edelson also served in two other Yale leadership positions - Director of the Yale Cancer Center, [5] between 2003 and 2008 and Deputy Dean of Yale School of Medicine from 2000 to 2003, overseeing all clinical departments. As Cancer Center Director he secured a renewed grant from the National Cancer Institute for $1.87 million annually, which has designated the Yale Cancer Center the only Comprehensive Cancer Center in southern New England as of the end of his tenure. [6] He also oversaw the building of the new cancer hospital and restructured the Cancer Center’s integration of clinical care and scientific inquiry. In 2008, he was named the first Lerner Professor of Dermatology. [7] As a mentor, sixteen of his physician trainees have gone on to lead Dermatology departments at US medical schools and abroad, including at leading departments at Yale, Harvard, Stanford, NYU and Oregon. [1]

Research

Five innovations define his investigative career. He discovered a cancer, elucidated its biology, originated a worldwide immunotherapy for it, led the team that found the key cell responsible for the efficacy of that therapy and directed advancing efforts to apply the derived principles to the development of personalized therapies for cancer and autoimmunity on a broad disease scale. As a researcher Edelson developed the ECP treatment for cutaneous T-cell lymphoma [5] during the 1980s. Much of his research during this time focused on looking to a patient's own immune system for therapeutics for different forms of cancer. This led to the first FDA-approved immunotherapy for cancer. [2] Part of his discovery was that ECP's induction of dendritic antigen presenting cells (DC) is ECP's therapeutic link with the normal immune system. From this discovery he also developed the concept of transimmunization, an enhanced form of ECP, and method of potential treatment for leukemias, lymphomas, lung cancer, heart and lung transplantation reactions and graft-versus-host disease following stem cell transplants. This research led to his founding of the company TransImmune AG. He also performed research into the use of photopheresis in cancer treatment, [8] using ultraviolet light. His experiments included partnering with Columbia, the University of California at San Francisco, and the universities of Düsseldorf, Vienna and Pennsylvania. [4] [9] While it had long been recognized by immunologists that dendritic cells (DCs) are the principal initiators of selective immunity and tolerance, the therapeutic potential of DCs had been unrealized due to a lack of knowledge of how these cells are produced by the body, where and when they are needed. The Edelson laboratory program reverse engineered the clinical efficacy of ECP into the discovery that those physiologic DCs (phDCs), which naturally function successfully in experimental animals and humans, are produced by controllable and tunable platelet signaling of monocyte-to-dendritic cell maturation. The broad therapeutic implications of this discovery are now being developed by a partnership between Yale University, the Federal Government, the Gates Foundation, and Transimmune AG.

In 2023 Edelson’s became the co-principal investigator on the first ever grant awarded by the Advanced Research Projects Agency for Health, for the implementation of mRNA vaccines for cancer as a part of the Federal Cancer Moonshot program. The project, entitled “Curing the Uncurable via RNA Encoded Immunogene Tuning”, was a collaboration between his lab at Yale, the University of Georgia, and co-principal investigator Philip Santangelo at Emory University. Part of the project is to enable researchers to program dendritic cells with synthetic mRNA so that the immune system can attack cancer cells while not affecting healthy cells. [10] Edelson has stated that this research is partially a long-term continuation of his early research at NCI. [11] Edelson’s work on controlling emerging microbial infections has been funded by the Gates Foundation. [1]

Recognition

Edelson is an elected fellow of both the American Society for Clinical Investigation and the Association of American Physicians. He is also recipient of the Society of Investigative Dermatology's Rothman Award for Career Contribution, [2] the Castle and Connolly's National Physician of the Year award, [12] the American Skin Association's National Mentorship Award, [13] and the Dermatology Foundation's Discovery Award and the International Society of Cutaneous Lymphoma Lifetime Achievement Award. [14] Of the more than two thousand graduates of the NIH Physician Scientist Training Program, he was one of eight selected physician-scientists whose investigative careers were featured in an eight-hour audiobook, narrated by actor Alan Alda, released by Audible.Com in December 2020, as a tribute to pivotal federally funded scientifically-driven medical advances.

Related Research Articles

Immunotherapy or biological therapy is the treatment of disease by activating or suppressing the immune system. Immunotherapies designed to elicit or amplify an immune response are classified as activation immunotherapies, while immunotherapies that reduce or suppress are classified as suppression immunotherapies. Immunotherapy is under preliminary research for its potential to treat various forms of cancer.

A cancer vaccine, or oncovaccine, is a vaccine that either treats existing cancer or prevents development of cancer. Vaccines that treat existing cancer are known as therapeutic cancer vaccines or tumor antigen vaccines. Some of the vaccines are "autologous", being prepared from samples taken from the patient, and are specific to that patient.

<span class="mw-page-title-main">Mycosis fungoides</span> Most common form of cutaneous T-cell lymphoma

Mycosis fungoides, also known as Alibert-Bazin syndrome or granuloma fungoides, is the most common form of cutaneous T-cell lymphoma. It generally affects the skin, but may progress internally over time. Symptoms include rash, tumors, skin lesions, and itchy skin.

<span class="mw-page-title-main">Cutaneous T-cell lymphoma</span> Medical condition

Cutaneous T-cell lymphoma (CTCL) is a class of non-Hodgkin lymphoma, which is a type of cancer of the immune system. Unlike most non-Hodgkin lymphomas, CTCL is caused by a mutation of T cells. The cancerous T cells in the body initially migrate to the skin, causing various lesions to appear. These lesions change shape as the disease progresses, typically beginning as what appears to be a rash which can be very itchy and eventually forming plaques and tumors before spreading to other parts of the body.

<span class="mw-page-title-main">Cancer immunotherapy</span> Artificial stimulation of the immune system to treat cancer

Cancer immunotherapy (immuno-oncotherapy) is the stimulation of the immune system to treat cancer, improving the immune system's natural ability to fight the disease. It is an application of the fundamental research of cancer immunology (immuno-oncology) and a growing subspecialty of oncology.

In medicine, photopheresis is a form of apheresis and photodynamic therapy in which blood is subject to apheresis to separate buffy coat from whole blood, chemically treated with 8-methoxypsoralen, exposed to ultraviolet light (UVA), and then returned to the patient. Activated 8-methoxypsoralen crosslinks DNA in exposed cells, ultimately resulting apoptosis of nucleated cells. The photochemically damaged T-cells returned to the patient appear to induce cytotoxic effects on T-cell formation. The mechanism of such “antitumor” action has not been elucidated.

<span class="mw-page-title-main">FMS-like tyrosine kinase 3 ligand</span> Protein-coding gene in the species Homo sapiens

Fms-related tyrosine kinase 3 ligand (FLT3LG) is a protein which in humans is encoded by the FLT3LG gene.

<span class="mw-page-title-main">Ralph M. Steinman</span> Canadian immunologist and cell biologist

Ralph Marvin Steinman was a Canadian physician and medical researcher at Rockefeller University, who in 1973 discovered and named dendritic cells while working as a postdoctoral fellow in the laboratory of Zanvil A. Cohn, also at Rockefeller University. Steinman was one of the recipients of the 2011 Nobel Prize in Physiology or Medicine.

<span class="mw-page-title-main">Resiquimod</span> Chemical compound

Resiquimod (R-848) is a drug that acts as an immune response modifier, and has antiviral and antitumour activity. It is used as a topical gel in the treatment of skin lesions such as those caused by the herpes simplex virus and cutaneous T cell lymphoma, and as an adjuvant to increase the effectiveness of vaccines. In an animal disease model, systemic administration of resiquimod-loaded nanoparticles has been shown to improve response rates to cancer immunotherapy with a checkpoint inhibitor through stimulation of tumor-associated macrophages. It has several mechanisms of action, being both an agonist for toll-like receptor 7 and 8, and an upregulator of the opioid growth factor receptor. On 28 April 2016, orphan designation (EU/3/16/1653) was granted by the European Commission to Galderma R&D, France for resiquimod to be used in the treatment of cutaneous T-cell lymphoma.

Gustav Gaudernack is a scientist working in the development of cancer vaccines and cancer immunotherapy. He has developed various strategies in immunological treatment of cancer. He is involved in several ongoing cellular and immuno-gene therapeutic clinical trials and his research group has put major efforts into the development of various T cell-based immunotherapeutic strategies.

<span class="mw-page-title-main">James P. Allison</span> American immunologist and Nobel laureate (born 1948)

James Patrick Allison is an American immunologist and Nobel laureate who holds the position of professor and chair of immunology and executive director of immunotherapy platform at the MD Anderson Cancer Center in Houston, Texas. Allison is Regental Professor and Founding-Director of James P. Allison Institute at the MD Anderson Cancer Center.

Brian V. Jegasothy was a dermatologist and visiting professor at over 50 Universities. and clinics, and was the Chairman of the Department of Dermatology at the University of Pittsburgh from 1987 to 1999.

The dendritic cell-based cancer vaccine is an innovation in therapeutic strategy for cancer patients.

Julianna Lisziewicz is a Hungarian immunologist. Lisziewicz headed many research teams that have discovered and produced immunotheraputic drugs to treat diseases like cancer and chronic infections like HIV/AIDS. Some of these drugs have been successfully used in clinical trials.

Jacques Banchereau is an internationally prominent French American immunologist and molecular biologist. As of 2022, he is Chief Scientific Officer at Immunai. He was formerly professor and director of immunological sciences at the Jackson Laboratory for Genomic Medicine and also the former chief science officer, senior vice president, and DTA head of inflammation & virology at Hoffman-La Roche. He is best known for his extensive research on dendritic cells with Nobel Laureate Ralph M. Steinman. He is the fifth most cited immunologist ranked by Times Higher Education's report.

Miram Merad is a French-Algerian professor in Cancer immunology and the Director of the Marc and Jennifer Lipschultz Precision Immunology Institute (PrIISM) at the Icahn School of Medicine at Mount Sinai (ISMMS) in New York, NY. She is the corecipient of the 2018 William B. Coley Award for Distinguished Research in Basic Immunology and a member of the United States National Academy of Sciences and the National Academy of Medicine.

<span class="mw-page-title-main">Duane Mitchell</span> American physician and research scientist

Duane A. Mitchell is an American physician-scientist and university professor. He is currently employed at the University of Florida College of Medicine, in Gainesville, Florida as the Assistant Vice President for Research, Associate Dean for Translational Science and Clinical Research, and Director of the University of Florida (UF) Clinical and Translational Science Institute. He is the Phyllis Kottler Friedman Professor in the Lillian S. Wells Department of Neurosurgery. and co-director of the Preston A. Wells Jr. Center for Brain Tumor Therapy. Mitchell is also the founder, President, and Chairman of iOncologi, Inc., a biotechnology company in Gainesville, FL specializing in immuno-oncology.

<span class="mw-page-title-main">Uğur Şahin</span> German oncologist and immunologist (born 1965)

Uğur Şahin is a German oncologist and immunologist. He is the founder and CEO of BioNTech, which developed one of the major vaccines against COVID-19. His main fields of research are cancer research and immunology.

<span class="mw-page-title-main">Carla V. Rothlin</span> Argentinian immunologist

Carla V. Rothlin is an Argentinian immunologist. She is a professor of immunobiology at Yale University, where she holds the Dorys McConnell Duberg Professorship, and also serves as a professor of pharmacology. Rothlin is the co-leader of the Cancer Immunology Program at Yale Cancer Center and a Howard Hughes Medical Investigator Faculty Scholar.

Thomas S. Kupper is an American physician, academic, and clinician. His work with clinical and research experience spans dermatology, cutaneous oncology, and immunology. He is the Thomas B. Fitzpatrick Professor at Harvard Medical School, and chairs the Departments of Dermatology at Brigham and Women's Hospital. He also leads the Cutaneous Oncology Disease Center at the Dana Farber Cancer Institute.

References

  1. 1 2 3 4 5 6 7 Hamm, Steve. "Serendipity in action". medicine.yale.edu.
  2. 1 2 3 4 "Richard Edelson, MD". medicine.yale.edu.
  3. ↑ "First Cancer Moonshot Award Announced at Yale School of Medicine". medicine.yale.edu.
  4. 1 2 Squire, Susan (February 1, 1987). "NEW CLUES TO THE IMMUNE SYSTEM (Published 1987)". The New York Times.
  5. 1 2 "What a Dermatologist Is and How to Become One: A Guide for Aspiring Doctors". US News & World Report. 10 December 2019. Retrieved 9 July 2023.
  6. ↑ "Edelson to step down as director of Yale Cancer Center". yaledailynews.com. 15 January 2008.
  7. ↑ "Dr. Richard Edelson is the first Lerner Professor of Dermatology". YaleNews. May 16, 2008.
  8. ↑ Writer, WILLIAM HATHAWAY; Courant Staff (July 2003). "A DOCTOR'S DREAM". courant.com.{{cite web}}: CS1 maint: multiple names: authors list (link)
  9. ↑ "Extracorporeal photopheresis - PMC - NCBI". www.ncbi.nlm.nih.gov.
  10. ↑ Salcerio, Carlos (September 7, 2023). "Research team secures $25 million grant to develop mRNA cancer vaccine". Yale Daily News.
  11. ↑ Backman, Isabella. "1st ARPA-H Grant: mRNA-Based Anti-Cancer and Anti-Microbial Vaccine Development". medicine.yale.edu.
  12. ↑ Dodson, Helen (February 28, 2012). "Edelson to be honored with National Physician of the Year award". YaleNews.
  13. ↑ "American Skin Association". www.americanskin.org.
  14. ↑ "Richard Edelson, M.D. '70, receives Discovery Award". medicine.yale.edu.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.